Rib-X Appoints MedImmune’s Peter Greenleaf to Board
January 20, 2010 07:33 AM Eastern Time
NEW HAVEN, Conn.--(EON: Enhanced Online News)--Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company
product pipeline based on its innovative discovery platform, today announced the appointment of Peter Greenleaf to the Company’s
Directors, succeeding Tony Zook.
Mr. Greenleaf is the senior vice president of commercial operations, corporate development & strategy at MedImmune Inc., and is
for MedImmune Ventures, a corporate venture capital fund within the AstraZeneca/MedImmune group of companies.
Mr. Greenleaf joined MedImmune from Centocor, Inc., where he served as franchise vice president, responsible for sales, marketin
planning and business development. Previously, he served in sales and marketing capacities with Boehringer Mannheim Corporation
Healthcare, Inc. Mr. Greenleaf holds a bachelor of science degree from Western Connecticut State University and a master's degre
administration from St. Joseph's University.
"Rib-X is very excited that Mr. Greenleaf has joined our Board. His extensive commercial and strategic expertise and depth of hand
pharmaceutical sales and marketing is invaluable to Rib-X as we move our lead antibiotic programs into late-stage development" sai
Froshauer, Ph.D., Founder and the President and Chief Executive Officer of Rib-X Pharmaceuticals.
Rib-X Pharmaceuticals, Inc. has an industry-leading pipeline of novel antibiotics targeting multidrug-resistant infections in significant
segments of the $25 billion antibiotics market. The Rib-X product portfolio has four core programs including two late-stage product
Delafloxacin and Radezolid, both potential best-in-class antibiotics being developed in market-preferred intravenous and oral formul
maximum flexibility. The foundation of the Rib-X product portfolio is its proven discovery technology, the Ribosome Antibiotic Bind
platform, using Nobel-prize-winning knowledge of ribosomal structure and mechanisms of antibiotic binding to create new chemical
antibiotics for a wide range of multidrug-resistant bacterial infections.
The Yates Network
Gina Nugent, 617-460-3579